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Abstract
Background: Fatty liver disease is characterized by the accumulation of fat vacuoles inside of the
hepatocytes. Non alcoholic fatty liver is associated with obesity, type 2 diabetes, dyslipemia, the
intake of certain drugs and with the so-called metabolic syndrome. However, there is little
information on the clinical relevance of this disorder as a healthcare problem in the general
population, since the studies published generally include a limited number of patients and the
diagnosis is established on the basis of clear biochemical alterations and liver biopsy.
Methods/Design: The aim of the study is the prevalence of non-alcoholic fatty liver disease in a
general adult population by hepatic ultrasonography.
A population-based, descriptive, transversal, multicentre study. Eighteen primary care centres of
the north of Barcelona and the Maresme Areas of Healthcare Management attending an urban and
semi-urban population of 360.000 inhabitants.
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A randomized sample of 786 subjects of 15 years or older were selected from the population and
assigned to the participating centres according to the Primary Care Information System (SIAP): This
population is practically the same as the general population of the area.
The following determinations will be carried out in all the participants: hepatic ultrasonography to
detect fatty liver, a questionnaire concerning liver diseases, alcohol intake, smoking and drug use,
physical examination including abdominal perimeter and body mass index and biochemical analysis
including liver function tests and parameters related to the metabolic syndrome and the HAIR
score.
Ultrasonographic diagnosis of fatty liver will be made according to established criteria (American
Gastroenterology Association) and diagnosis of metabolic syndrome according to the criteria of
the European Group for the Study of Insulin Resistance.
Discussion: This study will attempt to determine the prevalence of non alcoholic fatty liver
disease, as well as, the factors most frequently associated with the presence of this disease to
thereby achieve the most appropriate treatment and avoid the evolution of the disease.
Background
Fatty liver disease is characterized by the accumulation of
fat vacuoles in the cytoplasm of the hepatocytes, and is
usually a mild lesion which is generally detected in
chronic alcoholic patients [1].
Until the appearance of hepatic ultrasonography, fatty
liver was a disorder diagnosed only by liver biopsy in indi-
viduals presenting hepatomegaly with or without bio-
chemical abnormalities suggestive of liver disease [1,2].
At the beginning of the 1980s, a liver lesion was described
which could not be differentiated from that associated
with alcohol, and which covered a wide spectrum of pat-
terns including simple fatty liver, steatohepatitis, with
fatty vacuoles, necroinflammatory changes and a variable
grade of fibrosis which may finally progress to liver cirrho-
sis in subjects without significant alcohol consumption
[3,4]. Non alcoholic fatty liver is associated with factors
such as obesity, type 2 diabetes, dyslipemia, the intake of
certain drugs (amiodarone, oestrogens, and corticoids)
and with the so-called metabolic syndrome (obesity, type
2 diabetes, dyslipemia, and arterial hypertension) [5-9].
Few studies have evaluated the prevalence of fatty liver in
a general population. Along this line, the widest study
undertaken was performed in a sample of almost 7.000
subjects in Northern Italy. In this study the most prevalent
hepatic lesion was fatty liver (33% of the subjects with
excessive alcohol intake) but ultrasonographic diagnosis
was only performed in cases presenting clinical or analyt-
ical alterations suggestive of liver disease [10,11]. The
same authors have recently published the results of
another study with a new review of the prevalence and risk
factors associated with fatty liver in the same series of
patients and concluded that fatty liver is very prevalent
(20%) in the general population and is associated with
the different components of the metabolic syndrome
[12]. Thus, non alcoholic fatty liver may be the hepatic
component of the metabolic syndrome. Another study
published in Spain attempted to make an epidemiologic
approach to fatty liver by prospectively determining the
prevalence, diagnosed by abdominal ultrasonography of
1703 working males and studying the relationship with
alcohol intake and other risk factors such as obesity (body
mass index > 30), hypercholesterolemia and hyperglycae-
mia and found that 13.8% fulfilled ultrasonographic cri-
teria of fatty infiltration. Logistic regression analysis
identified alcohol consumption > 40 g/day, age, obesity
and elevated values of glycaemia, cholesterol and gam-
maglutamyltransferase as the main factors associated with
the presence of fatty liver in this population [13].
More recently a population study has been published
including 420 patients diagnosed with fatty liver not
related to alcohol from 1980 to 2000 in different primary,
secondary and tertiary healthcare centres in Minnesota.
The authors precisely defined the morbidity and mortality
associated with this disease. The patients had a mean age
of 49 years, two out of three were obese and had hypertrig-
lyceridemia, 36% were hypertensive, 26% had diabetes
and 36% presented altered baseline glycaemia. The mean
follow up of the patients was of 8 years. During this time
period 13% of the patients died, representing a mortality
greater than that expected in the general population (RR
1.34; p = 0.03). On multivariate analysis, the predictive
factors of mortality were age, the presence of cirrhosis and
surprisingly, altered baseline glycaemia. Liver disease con-
stituted the third cause of death in these patients follow-
ing neoplasms and ischaemic heart disease, in contrast
with the general population in whom liver diseases are the
thirteenth cause of death. Specifically speaking, during the
follow up period, 5% of the patients were diagnosed withBMC Gastroenterology 2007, 7:41 http://www.biomedcentral.com/1471-230X/7/41
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cirrhosis, 3% presented complications and 7 patients died
in relation to their chronic liver disease (1.7%) [14].
The pathogenesis of non alcoholic fatty liver is only par-
tially known, although it seems to be multifactorial. The
most widespread pathogenic theory is that of the double
impact in which the first is a resistance to peripheral insu-
lin resulting in the accumulation of fat in the liver, and the
second is chronic oxidative stress which leads to apoptosis
and/or hepatocellular necrosis, inflammation and fibrosis
[15,16].
As we have seen, the main risk factor for the development
of non alcoholic fatty liver is, therefore, obesity. It is well
known that the increase in the number of obese persons
within the general population has progressed up to the
point that the healthcare authorities consider it to be one
of the main healthcare problems for the near future and
making it one of the priorities for intervention and inves-
tigation. In addition, patients with non alcoholic fatty
liver who are overweight and/or obese are more to likely
to develop non alcoholic steatohepatitis, with a percent-
age of these patients evolving to more severe forms of liver
disease. We therefore believe that it is important to deter-
mine the HAIR score established by Dixon et al [17] to
know which patients may evolve to more severe forms of
the disease. The HAIR score includes: arterial hyperten-
sion, insulin resistance defined as: type 2 diabetes with
baseline glycaemia values greater than 110 mg/dl and less
than 126 mg/dl and two of the following factors: arterial
hypertension, triglycerides above 150 mg/dl and/or HDLc
< 35 in males and < 39 in females, a waist/hip index >
0.90 in males and 0.85 in females and/or BMI > 30 Kg/
m2, and ALT levels >40. Patients with a HAIR score ≥ 2 are
considered to have a high probability of developing non
alcoholic steatohepatitis.
The metabolic syndrome is constituted by the presence of
a series of factors within the same subject such as obesity,
arterial hypertension, dyslipemia or glucose intolerance
and has been on the rise in recent years. Several criteria are
used to define the metabolic syndrome, with the most
commonly used being those of the World Health Organi-
zation (WHO) [18] and those of the Adult Treatment
Panel III (ATP-III) of the National Cholesterol Education
Program (NCEP) [19]. The criteria of the WHO require the
presentation of some alteration in carbohydrate metabo-
lism, whether diabetes, abnormal glucose tolerance or
resistance to insulin. Two of the following criteria must
also be taken into account: arterial hypertension > 140/90
mm Hg, obesity (BMI = 30 Kg/m2), hypertriglyceridemia
≥ 150 mg/dL or cHDL values < 35 in males and < 40 in
females and microalbuminuria ≥ 20 μg/min. This defini-
tion places great importance on alterations in carbohy-
drate metabolism and insulin resistance as the elements
necessary for the diagnosis of the metabolic syndrome.
However, the definition by the WHO requires the pres-
ence of an alteration in glycaemia and does not place
importance on the presence on abdominal obesity which
is important to define insulin resistance. For this reason
the European Group for the Study of Insulin Resistance
(EGIR) has proposed several changes in the definition of
the WHO, such as the presence of obesity (waist perimeter
≥ 94 cm), fasting plasma insulin determination and
altered fasting glycaemia [20]. The criteria of ATP-III of the
NCEP are based on the presence of abdominal obesity (≥
88 cm in women and ≥ 102 cm in males), hypertriglycer-
idemia (≥ 150 mg/dL), low cHDL plasma values (<35 mh/
dL), arterial hypertension (≥ 130/85 mm Hg) and altered
fasting glycaemia (≥ 110 mg/dL). The criteria of the ATP-
III are more clinical and easier to apply than those of the
WHO, but the results of several studies have shown that
the ATP-III criteria overestimate the presence of the meta-
bolic syndrome. On the other hand, the criteria of the
ATP-III do not correlate with those using insulin resist-
ance as the fundamental element of diagnosis. Given the
importance of the metabolic syndrome in the diagnosis of
non alcoholic fatty liver and the discrepancies between
the two models, we believe it may be useful to analyze
both models in all the subjects to determine wihch model
best defines the metabolic syndrome.
Objectives
Main objectives
1. Determine the prevalence of non alcoholic fatty liver in
apparently healthy adults who do not request medical
care and who have undergone a hepatic ultrasongraphy.
2. Describe the associated characteristics of these subjects
based on: sociodemographic variables, history of liver dis-
ease and associated risk factors.
3. Evaluate the influence of each of the components mak-
ing up the metabolic syndrome and the risk of having non
alcoholic fatty liver.
4. Identify the subjects who may progress to chronicity
and the factors favouring progresión.
Secondary objectives
1. Identify a cohort of patients with fatty liver with no evi-
dence of previous liver disease to perform a prospective
follow up.
Methods/Design
We will carry out a descriptive, transversal, population-
based, multicentre study in apparently healthy adults
(older than or equal to 15 years of age) or subjects not
requesting medical care who have undergone a hepatic
ultrasonography. The study has been approved by the Eth-BMC Gastroenterology 2007, 7:41 http://www.biomedcentral.com/1471-230X/7/41
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ical Committee of Clinical Investigation, Jordi Gol i
Gurina Foundation.
Study subjects
This will be a multicentre study including the participa-
tion of Primary Care teams covering a population of
360,000 inhabitants of an urban, and semi-rural zone of
the North of Barcelona and the Maresme, Spain.
Inclusion criteria
Adult population of both sexes from these Primary Care
teams between the age of 15 and 80 who wish to volun-
tarily participate in the study and who have signed a writ-
ten informed consent form to participate.
Exclusion criteria
Alcohol intake > 30 g/day in males and > 20 g/day in
females. Presence of chronic liver disease. Presence of the
surface antigen of the hepatitis B virus or the presence of
antibodies versus hepatitis C. Subjects with conditions or
diseases hindering data collection and follow up of the
study such as, incapacitating diseases, cognitive deteriora-
tion, institutionalized patients or subjects with no fixed
address in any of the basic areas of the study. Subjects who
do not provide written informed consent to participate in
the study.
Sample size
With an alpha risk of 0.05 for a precision of ± 0.03 per-
centage units in a bilateral contrast for an estimated pro-
portion of 0.20 a randomized sample proportional to 683
subjects is required. Considering that 15% of the popula-
tion will present alcohol intake or some previous liver dis-
ease, the number of patients to study in this percentage is
increased making a total of 786 individuals necessary to
fulfil the final sample size.
Selection method
A randomized sample of the population assigned and
obtained through the SIAP (Primary Care Information
System), will be stratified in proportion to the population
assigned to each of the Primary Care teams participating
in the study. It should be pointed out that the population
assigned is practically equivalent to the updated munici-
pal pattern.
Phase I
The resulting variable is the ultrasonographic diagnosis of
fatty liver. The diagnosis of fatty liver will be established
according to the standard criteria accepted by the Ameri-
can Gastroenterology Association [21]: An increase in
hepatic echogenicity taking renal echogenicity as a refer-
ence, the presence of enhancement and lack of differenti-
ation in periportal intensity and the vesicular wall due to
great hyperechogenicity of the parenchyma. The degree of
involvement will be standardized with a semiquantitative
scale of the degree of hepatic enhancement.
The following covariables will be evaluated in the study
subjects:
1. Sociodemographic variables: age, sex, occupation, edu-
cation and place of residence.
2. Clinical history including:
2.1 Personal history of: liver disease, biliary lithiasis, sur-
gical interventions.
2.2 Presence of comorbidities: obesity and being over-
weight, type 2 diabetes, dyslipemia and arterial hyperten-
sion.
2.3 Alcohol intake: determine the type and quantity of
beverages consumed.
2.4 Smoking habit.
2.5 Habitual drug use: history of drug use during the pre-
vious six months.
3. Physical examination:
3.1 Antropometric data: weight, height, abdominal obes-
ity and body mass index.
3.2 Determination of arterial pressure.
4. Analytical determinations:
4.1 Blood analysis including: a complete hemogram, gly-
caemia, glycosylated haemoglobyn, urea, creatinine, uric
acid, a lipid study (cholesterol, triglycerides, HDL, LDL)
and liver function tests, including hepatitis markers (sur-
face antigen of the hepatitis B virus and antibodies versus
the hepatitis C virus).
4.2 Baseline insulin levels will be determined by the
immunochemoluminescence method.
4.3 Determination of insulin resistance will be estalished
with the HOMA method (homeostasis model assess-
ment). ([glycaemia(mmol/L)/insulin (mU/L)]/22.5).
4.4 A sample of the first urine in the morning will be taken
to determine microalbuminuria.
5. Determination of the HAIR score [17].BMC Gastroenterology 2007, 7:41 http://www.biomedcentral.com/1471-230X/7/41
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6. Diagnosis of the metabolic syndrome: This will be
made according to the criteria of the WHO [18] modified
by the European Group for the Study of Insulin Resistance
[20], and the National Cholesterol Education Program
(NCEP) [19].
Phase II
Patients with diagnosed liver disease will receive the nor-
mal control and follow up by their reference physician.
Patients with fatty liver with no evidence of liver disease
will be advised to modify their habits and risk factors and
will initiate annual control and ultgrasonographic follow
up. The resulting variable in this phase will be the persist-
ence, reversal or progression of liver involvement. This
subgroup of subjects will provide a cohort of patients to
obtain data on the natural history of the disease in future
studies.
Plan of analysis
Data will be introduced into an ACCESS type database
and then analysed. The prevalence of fatty liver will be
estimated with a confidence interval of 95%.
A descriptive univariate and bivariate statistical analysis
will be performed, analysing the qualitative variables with
chi-squared test and the quantitative variables with the
Students-t- test. Statistical significance will be established
at 5% for all the bivariate analyses and contrasts will be
considered at a bilateral level. Multivariate analysis will
also be undertaken with logistic regression models
(dependent variable presence/absence of fatty liver)
allowing adjustment of the effect of the different inde-
pendent variables on the presence of non alcoholic fatty
liver.
Discussion
Non alcoholic fatty liver is possibly the most common
cause of an elevation in transaminases in adults [22]. Tak-
ing into account the progressive increase in the prevalence
of obesity, type 2 diabetes, and dyslipemia in the popula-
tion, studies performed in the USA consider that the prev-
alence of non alcoholic fatty liver would be much higher
than the prevalence of hepatitis C virus infection esti-
mated to be 1.8% [7]. With the increase in the prevalence
of these associated diseases, non alcoholic fatty liver may
become one of the most frequent causes of chronic liver
disease in Western countries [23].
As a consequence of periodic health examinations in the
general population and the greater accessibility to diag-
nostic imaging tests in primary care, minimum hepatic
biochemical alterations are increasingly found which are
only correlated with an ultrasonographic diagnosis of
fatty liver. In Spain the diagnosis of non alcoholic fatty
liver is increasingly more frequent due to the interest
given and the increase in obesity, manifesting during ado-
lescence. Thus, if it used to be considered a disease mainly
affecting middle-aged, obese, and in many cases diabetic,
women, it has been shown to affect both sexes equally
after adolescence [24].
Another of the limitations of the study is related to the use
of hepatic ultrasonography for the diagnosis of fatty liver.
The gold standard for diagnosis of this disease is liver
biopsy. Nonetheless, studies comparing the diagnostic
utility of ultrasonography compared with liver biopsy
have shown a sensitivity of greater than 90% and a specif-
icity of greater than 80% for ultrasonography in detecting
the presence of fatty liver. The main limitation seems to be
the difficulty in detecting the presence of fatty liver when
the infiltration is of less than 30% of the hepatic content.
Another limitation of ultrasonography is the lack of infor-
mation regarding the histologic changes associated with
disease progression. To achieve this liver biopsy would be
required which, in our case would be referred to the refer-
ence hospital on both clinical and biochemical suspicion
of progression. Therefore, ultrasonography of the liver is
currently the test of reference for the detection of fatty liver
at a population level.
Although increasingly more knowledge on this disease
has been obtained, several important aspects remain to be
elucidated, such as the establishment of the real preva-
lence of this disease, the identification of the cases which
may progress to chronicity, the factors favouring progres-
sion, the search for non invasive methods to detect the
presence of fibrosis and clinical trials with the different
treatments which have been proposed.
To date no study of these characteristics has been under-
taken in Primary Care and in a population base in Spain.
Thus, a study such as this may have important social,
healthcare and economic impact since it will allow the
estimation of the real presence of a silent healthcare prob-
lem with potentially severe consequences which may, in
part, be avoided by early intervention. These defining
characteristics (high prevalence and possibility of early
intervention) making non alcoholic fatty liver a health-
care problem which should, typically, be approached
from Primary Care but which seems to be under-evaluated
and underdiagnosed. This is the framework within which
this project is integrated: the estimation of the prevalence
and quantification of the underdiagnosis in the general
population.
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